G De Filippo1,2,3, D Rendina4, F Moccia5, V Rocco5, A Campanozzi6. 1. Pediatric Endocrinology Unit, Gaetano Rummo Hospital, Benevento, Italy. gianpaolo.defilippo@bct.aphp.fr. 2. Assistance Publique-Hôpitaux de Paris, Service d'Endocrinologie et Diabétologie Pédiatrique, Hôpitaux Universitaires Paris Sud, Le Kremlin-Bicêtre, France. gianpaolo.defilippo@bct.aphp.fr. 3. Service d'Endocrinologie et Diabétologie Pédiatrique, Centre Hospitalier Universitaire de Bicêtre, 78, rue du Général Leclerc, 94275, Le Kremlin-Bicêtre, France. gianpaolo.defilippo@bct.aphp.fr. 4. Department of Clinical Medicine and Surgery, Federico II University of Naples, Naples, Italy. 5. Biochemistry Unit, Gaetano Rummo Hospital, Benevento, Italy. 6. Pediatrics, Department of Medical and Surgical Sciences, University of Foggia, Foggia, Italy.
Abstract
BACKGROUND/AIM: To study the characteristics of interleukin 6 (IL6), soluble form of interleukin 6 receptor (sILR)/IL6 complex in obese children and adolescents and its relationship with insulin resistance (IR). SUBJECTS AND METHODS: 66 obese children and adolescents [34 boys, mean age 10.3 ± 2.9 years, z-score of body mass index (BMI) 4.76 ± 1.36] and 24 non-obese healthy sex- and age-matched controls. Fasting levels of glucose, insulin, IL6, sIL6, sgp130 were measured. IR was assessed by homeostasis model assessment of IR (HOMA-IR). RESULTS: Obese subjects showed increased levels of insulin and IL-6 and higher HOMA-IR compared to controls (117.67 ± 50.9 vs. 62.42 ± 29.4 pmol/L, 2.73 ± 0.98 vs. 1.07 ± 0.41 pg/ml and 4.03 ± 2.16 vs. 1.83 ± 1.05 for insulin, IL-6 and HOMA-IR, respectively, p < 0.01 in all cases). sIL-6R levels were significantly lower in obese subjects (34.7 ± 14.2 vs. 55.6 ± 15.2 ng/ml in controls, p = 0.005), whereas sgp130 levels were not significantly different. In obese subjects, IL-6 directly correlated with z-score BMI (r = 0.481, p = 0.009) and with waist-to-height ratio (r = 0.494, p = 0.007), while sIL6-R was inversely related to HOMA-IR (r = -0.522, p = 0.002). Insulin resistant subjects showed higher levels of IL6 and lower levels of sIL6R (3.31 ± 0.72 vs. 2.25 ± 0.64 pg/ml, p = 0.020 and 25.3 ± 9.3 vs. 42.5 ± 10.4 ng/ml, p = 0.013, respectively). CONCLUSIONS: In obese children and adolescents, IR is associated with elevated levels of IL-6 and diminished values of sIL-6R.
BACKGROUND/AIM: To study the characteristics of interleukin 6 (IL6), soluble form of interleukin 6 receptor (sILR)/IL6 complex in obesechildren and adolescents and its relationship with insulin resistance (IR). SUBJECTS AND METHODS: 66 obesechildren and adolescents [34 boys, mean age 10.3 ± 2.9 years, z-score of body mass index (BMI) 4.76 ± 1.36] and 24 non-obese healthy sex- and age-matched controls. Fasting levels of glucose, insulin, IL6, sIL6, sgp130 were measured. IR was assessed by homeostasis model assessment of IR (HOMA-IR). RESULTS:Obese subjects showed increased levels of insulin and IL-6 and higher HOMA-IR compared to controls (117.67 ± 50.9 vs. 62.42 ± 29.4 pmol/L, 2.73 ± 0.98 vs. 1.07 ± 0.41 pg/ml and 4.03 ± 2.16 vs. 1.83 ± 1.05 for insulin, IL-6 and HOMA-IR, respectively, p < 0.01 in all cases). sIL-6R levels were significantly lower in obese subjects (34.7 ± 14.2 vs. 55.6 ± 15.2 ng/ml in controls, p = 0.005), whereas sgp130 levels were not significantly different. In obese subjects, IL-6 directly correlated with z-score BMI (r = 0.481, p = 0.009) and with waist-to-height ratio (r = 0.494, p = 0.007), while sIL6-R was inversely related to HOMA-IR (r = -0.522, p = 0.002). Insulin resistant subjects showed higher levels of IL6 and lower levels of sIL6R (3.31 ± 0.72 vs. 2.25 ± 0.64 pg/ml, p = 0.020 and 25.3 ± 9.3 vs. 42.5 ± 10.4 ng/ml, p = 0.013, respectively). CONCLUSIONS: In obesechildren and adolescents, IR is associated with elevated levels of IL-6 and diminished values of sIL-6R.
Authors: Vitor Rosetto Muñoz; Rafael Calais Gaspar; Barbara Moreira Crisol; Guilherme Pedron Formigari; Marcella Ramos Sant'Ana; José Diego Botezelli; Rodrigo Stellzer Gaspar; Adelino S R da Silva; Dennys Esper Cintra; Leandro Pereira de Moura; Eduardo Rochete Ropelle; José Rodrigo Pauli Journal: J Physiol Sci Date: 2017-07-14 Impact factor: 2.781
Authors: Risa M Wolf; Andrew E Jaffe; Kimberley E Steele; Michael A Schweitzer; Thomas H Magnuson; Andrew Wolfe; G William Wong Journal: J Clin Endocrinol Metab Date: 2019-03-01 Impact factor: 5.958
Authors: S Spanou; D Kalogiannis; E Zapanti; M Gazouli; I A Sfontouris; C Siristatidis; George Mastorakos Journal: J Assist Reprod Genet Date: 2018-04-04 Impact factor: 3.412
Authors: Helena U Westergren; Sara Svedlund; Remi A Momo; Juuso I Blomster; Karin Wåhlander; Erika Rehnström; Peter J Greasley; Regina Fritsche-Danielson; Jan Oscarsson; Li-Ming Gan Journal: Cardiovasc Diabetol Date: 2016-02-19 Impact factor: 9.951
Authors: Ola M Ibrahim; Azza A Gabre; Sara F Sallam; Inas R El-Alameey; Rania N Sabry; Essam M Galal; Sawsan M Tawfik; Waheba A Zarouk; Rehab M Mosaad; Abeer Ramadan Journal: Open Access Maced J Med Sci Date: 2017-10-17